x NoneEntity Type
0001558569
 
x Corporation
o Limited Partnership
o Limited Liability Company
o General Partnership
o Business Trust
o Other
Name of Issuer
 iSpecimen Inc.
Jurisdiction of Incorporation/OrganizationDELAWARE 
Year of Incorporation/Organization
  x Over Five Years Ago
  o Within Last Five Years (Specify Year)  
  o Yet to Be Formed 



2. Principal Place of Business and Contact Information
Name of Issuer 
 iSpecimen Inc. 
Street Address 1Street Address 2
 450 BEDFORD STREET 
CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
 LEXINGTON MASSACHUSETTS 02420 781-301-6700 



3. Related Persons
Last NameFirst NameMiddle Name
IanelliChristopherJ.
Street Address 1Street Address 2
450 Bedford Street
CityState/Province/CountryZIP/Postal Code
LexingtonMASSACHUSETTS02420
Relationship: x Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
RossAndrew
Street Address 1Street Address 2
450 Bedford Street
CityState/Province/CountryZIP/Postal Code
LexingtonMASSACHUSETTS02420
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
SchollGeorge
Street Address 1Street Address 2
450 Bedford Street
CityState/Province/CountryZIP/Postal Code
LexingtonMASSACHUSETTS02420
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
MullanJill
Street Address 1Street Address 2
450 Bedford Street
CityState/Province/CountryZIP/Postal Code
LexingtonMASSACHUSETTS02420
Relationship: x Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

 
Last NameFirst NameMiddle Name
CurleyTracy
Street Address 1Street Address 2
450 Bedford Street
CityState/Province/CountryZIP/Postal Code
LexingtonMASSACHUSETTS02420
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
BielakBenjamin
Street Address 1Street Address 2
450 Bedford Street
CityState/Province/CountryZIP/Postal Code
LexingtonMASSACHUSETTS02420
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
GullansSteven
Street Address 1Street Address 2
450 Bedford Street
CityState/Province/CountryZIP/Postal Code
LexingtonMASSACHUSETTS02420
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
Brooks IIIJohnL.
Street Address 1Street Address 2
450 Bedford Street
CityState/Province/CountryZIP/Postal Code
LexingtonMASSACHUSETTS02420
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

 
Last NameFirst NameMiddle Name
LawrenceMargaretH.
Street Address 1Street Address 2
450 Bedford Street
CityState/Province/CountryZIP/Postal Code
LexingtonMASSACHUSETTS02420
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

 


4. Industry Group
o Agriculture Health Care o Retailing
 Banking & Financial Services   o Biotechnology o Restaurants
  o Commercial Banking   o Health Insurance Technology
  o Insurance  o Hospitals & Physicians  o Computers
  o Investing  o Pharmaceuticals  o Telecommunications
  o Investment Banking  x Other Health Care  o Other Technology
  o Pooled Investment Fund

    Travel
  o Other Banking & Financial Services o Manufacturing  o Airlines & Airports
 Real Estate  o Lodging & Conventions
  o Commercial  o Tourism & Travel Services
  o Construction  o Other Travel
  o REITS & Finance o Other
  o Residential 
  o Other Real Estate 
o Business Services 
 Energy 
  o Coal Mining 
  o Electric Utilities 
  o Energy Conservation 
  o Environmental Services 
  o Oil & Gas 
  o Other Energy 


5. Issuer Size
Revenue RangeAggregate Net Asset Value Range
o No Revenues o No Aggregate Net Asset Value
o $1 - $1,000,000 o $1 - $5,000,000
o $1,000,001 - $5,000,000 o $5,000,001 - $25,000,000
o $5,000,001 - $25,000,000 o $25,000,001 - $50,000,000
o $25,000,001 - $100,000,000 o $50,000,001 - $100,000,000
o Over $100,000,000 o Over $100,000,000
x Decline to Disclose o Decline to Disclose
o Not Applicable o Not Applicable


6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
o Rule 504(b)(1) (not (i), (ii) or (iii)) o Rule 505
o Rule 504 (b)(1)(i) x Rule 506(b)
o Rule 504 (b)(1)(ii) o Rule 506(c)
o Rule 504 (b)(1)(iii) o Securities Act Section 4(a)(5)
  o Investment Company Act Section 3(c)

7. Type of Filing
x New Notice Date of First Sale 2021-12-01 o First Sale Yet to Occur
o Amendment

8. Duration of Offering
Does the Issuer intend this offering to last more than one year? o Yes x No

9. Type(s) of Securities Offered (select all that apply)
o Pooled Investment Fund Interests x Equity
o Tenant-in-Common Securities o Debt
o Mineral Property Securities x Option, Warrant or Other Right to Acquire Another Security
x Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security o Other (describe)
  


10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? o Yes x No
 
Clarification of Response (if Necessary) 
  

11. Minimum Investment
Minimum investment accepted from any outside investor$ 0 USD

12. Sales Compensation
RecipientRecipient CRD Number o None
 ThinkEquity LLC 20996
(Associated) Broker or Dealer x None(Associated) Broker or Dealer CRD Number x None
    
Street Address 1Street Address 2
 17 State Street 22nd Floor
City State/Province/CountryZIP/Postal Code
 New York NEW YORK 10004
State(s) of Solicitation o All States o Foreign/Non-US
 CONNECTICUT
 NEW YORK
 

 



13. Offering and Sales Amounts
Total Offering Amount $ 20999988 USD o Indefinite
Total Amount Sold $ 20999988 USD 
Total Remaining to be Sold $ 0 USD o Indefinite
 
Clarification of Response (if Necessary)
  


14. Investors
o Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering
 
  Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 4


15. Sales Commissions & Finders’ Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions$ 1334999 USD o Estimate
Finders' Fees$ 0 USD o Estimate
 
Clarification of Response (if Necessary)
  


16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
 $ 0 USD o
iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more iSpecimen Charts.
iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more iSpecimen Charts.

Ispecimen Inc. News

iSpecimen to Report First Quarter 2024 Financial Results on May 7, 2024
Thursday 25 April 2024 (5 days ago) • GlobeNewswire Inc.
iSpecimen Reports Full Year 2023 Results
Thursday 14 March 2024 (2 months ago) • GlobeNewswire Inc.
iSpecimen Reschedules Full Year 2023 Earnings Release and Conference Call
Tuesday 12 March 2024 (2 months ago) • GlobeNewswire Inc.
iSpecimen to Report Full Year 2023 Financial Results on March 13, 2024
Tuesday 5 March 2024 (2 months ago) • GlobeNewswire Inc.
Form 8-K - Current report
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)
Form 424B5 - Prospectus [Rule 424(b)(5)]
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Thursday 15 February 2024 (2 months ago) • Edgar (US Regulatory)
Form 5 - Annual statement of changes in beneficial ownership of securities
Thursday 8 February 2024 (3 months ago) • Edgar (US Regulatory)
iSpecimen and TriMetis Life Sciences Announce Strategic Partnership to Help Transform Tissue-Based Research
Tuesday 23 January 2024 (3 months ago) • GlobeNewswire Inc.
Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET
Monday 22 January 2024 (3 months ago) • GlobeNewswire Inc.
iSpecimen to Participate in Maxim Group Healthcare IT Virtual Conference, January 24 & 25, 2024
Thursday 18 January 2024 (3 months ago) • GlobeNewswire Inc.
Form 8-K - Current report
Thursday 21 December 2023 (4 months ago) • Edgar (US Regulatory)

More Ispecimen Inc. News Articles